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Abstract
Background: The precursor peptide of atrial natriuretic 
peptide (MR-proANP) has a physiological role in fluid 
homeostasis and is associated with mortality and adverse 
clinical outcomes in heart failure patients. Little is known 
about the prognostic potential of this peptide for long-term 
mortality prediction in community-dwelling patients. We 
evaluated associations of MR-proANP levels with 10-year 
all-cause mortality in patients visiting their general prac-
titioner for a respiratory tract infection.
Methods: In this post-hoc analysis including 359 patients 
(78.5%) of the original trial, we calculated cox regression 
models and area under the receiver operating characteris-
tic curve (AUC) to assess associations of MR-proANP blood 
levels with mortality and adverse outcome including 
death, pulmonary embolism, and major adverse cardiac 
or cerebrovascular events.
Results: After a median follow-up of 10.0 years, 9.8% of 
included patients died. Median admission MR-proANP 
levels were significantly elevated in non-survivors com-
pared to survivors (80.5 pmol/L, IQR 58.6–126.0; vs. 45.6 
pmol/L, IQR 34.2–68.3; p < 0.001) and associated with 
10-year all-cause mortality (age-adjusted HR 2.0 [95% CI 
1.3–3.1, p = 0.002]; AUC 0.79). Results were similar for day 
7 blood levels and also for the prediction of other adverse 
outcomes.
Conclusions: Increased MR-proANP levels were associ-
ated with 10-year all-cause mortality and adverse clinical 
outcome in a sample of community-dwelling patients. If 
diagnosis-specific cut-offs are confirmed in future stud-
ies, this marker may help to direct preventive measures in 
primary care.
Keywords: all-cause mortality; atrial natriuretic peptide; 
general practitioner; MR-proANP; primary care.
Introduction
The use of biomarkers for risk assessment in different 
cardiovascular (CV), infectious and systemic diseases 
has gained influence during the last years [1–5]. Among 
promising markers, natriuretic peptides such as atrial 
natriuretic peptide (ANP) have emerged due to their 
prognostic value for poor outcomes in several CV, meta-
bolic and infectious diseases [6–11]. ANP is mainly pro-
duced by cardiomyocytes in the atrium of the heart and 
mostly known for its regulation of natriuresis and diure-
sis [12–14]. It has an important role in fluid homeostasis, 
decreases blood pressure and modulates endothelium 
permeability [15–18]. The secretion of ANP is triggered by 
several pathophysiological mechanisms such as myocyte 
stretch, inflammation, ischemia, fibrosis and hypertrophy 
of the ventricle [19, 20]. The derivate of the precursor, the 
biologically active form of ANP and the biologically inac-
tive fragments such as mid-regional pro-atrial natriuretic 
peptide (MR-proANP) are measurable and serve as a more 
reliable analyte for measurement since ANP has a short 
half-life of only 3–4 min [21–23].
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Several reports found circulating MR-proANP levels to 
be predictive of mortality in the short- and long-term as 
well as other adverse outcomes, such as disease- specific 
complications or severity of illness and admission to 
the intensive care unit [1, 5, 24–27]. Previous research 
has focused on the association of MR-proANP levels and 
patients with heart failure [28–32]. Also, patients with 
lower respiratory tract infections have higher levels of 
MR-proANP as compared to healthy cohorts [27, 33]. The 
highest levels are found in pneumonia patients not sur-
viving their disease [34]. Most of this research, however, 
focused on hospitalized patients with higher severity and 
data on the long-term prognostic value of MR-proANP in 
community-dwelling patients is still limited [35–39].
Herein, the purpose of this prospective observational 
10-year follow-up was to investigate the potential of MR-
proANP as a prognostic biomarker for prediction of long-
term all-cause mortality and adverse clinical outcomes in 
a general practitioner setting.
Materials and methods
Study design and setting
This 10-year post-hoc analysis of a prognostic marker is based on 
blood samples from a previous trial (PARTI trial) published in 2008 
[40]. The design of the initial trial has been reported elsewhere (isrctn.
org; Identifier: ISRCTN73182671) and a study protocol was published 
beforehand [41]. In brief, the randomized, multicentre, non-inferior-
ity trial investigated effects of procalcitonin (PCT)-guided antibiotic 
therapy in primary care patients presenting with an acute respiratory 
tract infection (ARTI). Inclusion criterion was an upper or lower ARTI 
with physician’s intention for a treatment with antibiotics. Patients 
were either randomized into a PCT-guided group or a standard 
approach group. In the PCT-guided group, the use of antibiotics was 
more or less strongly discouraged based on predefined PCT cut-off 
ranges (procalcitonin level  ≥  0.1 μg/L or  ≤  0.25 μg/L) [42]. The control 
group followed evidence-based guidelines for use of antibiotics.
The Local Ethics Committee of the University Hospital Basel 
(EKBB) approved the trial protocol as well as the 10-year follow-up 
and all procedures conformed with the Declaration of Helsinki. Writ-
ten informed consent was obtained from involved general practition-
ers and patients for the initial PARTI trial.
A similar 10-year post-hoc analysis of the prognostic biomarker 
copeptin, based on the same blood samples from the PARTI trial, has 
been published recently and showed that copeptin was associated 
with 10-year all-cause mortality [43].
Analysis of blood biomarkers
Blood samples of every patient were collected and stored at the cen-
tral laboratory of the University Hospital in Basel. MR-proANP was 
measured by batch analysis in frozen (– 80 ° ) and stored leftover 
samples. Determination of MR-proANP plasma levels was performed 
by sandwich immunoassay (SERISTRA®, B.R.A.H.M.S AG, Hennings-
dorf/Berlin, Germany) with a functional sensitivity of 11 pmol/L and 
a lower detection limit of 4.3 pmol/L [44].
Data collection and outcomes
The initial sample included 458 adult patients with an ARTI, of 
which 359 (78.4%) could be contacted to assess long-term outcomes 
(see Supplemental Table 1 for difference in the overall cohort and the 
included patients). For the current analysis, we performed follow-up 
interviews with all initially involved general practitioners, patients 
and/or relatives based on their availability between April 2015 and 
August 2015. We performed an outcome assessment using system-
atic questionnaires. In these questionnaires, we also retrospectively 
asked for CV risk factors and comorbidities at baseline. Also, the reg-
ister of deaths of the cantons Basel-Stadt and Basel-Land was con-
sulted if no information about vital status was available.
We contacted the same general practitioners that collected the 
original data and 276 patients were assessed through 40 cooperating 
primary care physicians. Seventy-three patients and/or their relatives 
could be contacted by phone calls, nine patients were detected via 
the register of deaths of the cantons Basel-Stadt and Basel-Land and 
one patient died in the 28-day follow-up period of the initial trial.
Our primary outcome was 10-year all-cause mortality. Second-
ary outcomes were defined as adverse outcome events including 
death, pulmonary embolism, and major adverse cardiac or cerebro-
vascular events (MACCE) including cardiac infarction, cardiac arrest, 
stroke and transient ischemic attack. We also looked separately at 
MACCE and stroke as secondary outcomes. These endpoints were 
assessed by self- and general practitioner-report only and assess-
ment was blinded to MR-proANP blood levels.
Statistical analysis
Statistical analyses were performed using STATA 12.1 (STATA Corp, 
College Station, TX, USA).
Categorical variables are expressed as percentages (numbers) 
and continuous variables as medians (interquartile ranges [IQRs]), 
unless stated otherwise. If applicable, 95% confidence intervals 
(CIs) are presented. The χ2 (Wald) test is used for frequency com-
parisons, the nonparametric (Mann-Whitney-U) test for two-sample 
comparisons. We used univariable, bivariable (adjusting for age) as 
well as a fully adjusted model (adjusting for age, gender, randomi-
sation arm, antibiotic use initially, smoking history, comorbidities 
(COPD [chronic obstructive pulmonary disease], arterial hyperten-
sion, dyslipoproteinemia and diabetes) and type of infection) cox 
regression analysis to evaluate the association of MR-proANP with 
primary and secondary outcomes. We report hazard ratios (HRs) and 
95% CIs as a measure of association for time to event data and C-Sta-
tistics (area under the curve [AUC]) as a measure of discrimination. 
Since the distribution of raw biomarker data was skewed, we used 
a natural logarithm (base e) transformation. Thereafter, the distri-
bution of the biomarker data approximated a normal distribution. 
HR thereby corresponds to a nearly one-fourth-unit increase in the 
explanatory variable and to a 2.72-fold increase in log transformed 
biomarker levels. Further, for illustration, we present Kaplan-Meier 
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survival estimates of long-term survival by quartiles of MR-proANP 
levels. A post-hoc power analysis looking at mean differences in 
baseline MR-proANP blood levels in the two groups of 10-year sur-
vivors and 10-year non- survivors shows that our study had a power 
of 83% to detect the observed increase in mean MR-proANP from 57 
pmol/L (standard deviation [SD] 40) to 140 pmol/L (SD 167).
Results
Baseline characteristics
Baseline characteristics of patients who could be con-
tacted for long-term outcomes (n = 359) as well as strati-
fied by 10-year survival status are presented in Table 1. The 
median age was 47.9 (IQR 34.0–63.0) and 137 (38.2%) were 
male. Concerning CV risk factors at baseline, 54 (15.3%) 
had a positive CV family history and 119 (33.1%) a history 
of smoking, 58 (16.2%) hypertension and dyslipoproteine-
mia was found in 35 patients (15.3%).
The median blood value of MR-proANP levels meas-
ured at the day of randomization was 47.7 pmol/L (IQR 
35.0–75.5; n = 350) and 54.7 pmol/L (IQR 37.5–79.3; n = 334) 
at day 7 after randomization.
Primary outcome: 10-year all-cause mortality
During the 10.0 (IQR 9.5–10.3) years of follow-up, 35 patients 
(9.8%) died. Non-survivors had higher median baseline MR-
proANP blood levels (pmol/L) compared to survivors (80.5, 
IQR 58.6–126.0; vs. 45.6, IQR 34.2–68.3; p < 0.001). Similarly, 
day 7 blood levels also showed significant differences (91.4, 
IQR 63.1–150.0; vs. 52.1, IQR 37.0–73.7, p < 0.001). To illus-
trate the association with the proportion of survivors, we 
generated Kaplan-Meier curves (Figure  1), with patients 
stratified based on MR-proANP blood level quartiles (Q 1–3 
vs. Q 4). Mortality was increased in patients in the highest 
MR-proANP quartile compared to quartiles 1–3. Also, as 
demonstrated in Table 2, we found significant results in cox 
Table 1: Baseline characteristics overall and by 10-year survival status.
Characteristics   Patients with long-
term outcomes
n = 359
  10-year 
survivors
n = 324 
  10-year 
non-survivors
n = 35 
  p-Value
Demographic characteristics
 Age in years, median (IQR)   45.0 (34.0, 63.0)  43.5 (31.0, 58.5)  77.0 (68.0, 81.0)  < 0.001
 Male, n (%)   137 (38.2%)  116 (35.8%)  21 (60.0%)  0.005
CV risk factors
 Positive family history, n (%)   54 (15.3%)  52 (16.1%)  2 (6.7%)  0.17
 Smoker or former smoker, n (%)   119 (33.1%)  103 (31.8%)  16 (45.7%)  0.096
 Pack years, median (IQR)   20.0 (2.5, 40.0)  20.0 (3.0, 35.0)  47.0 (2.0, 76.0)  0.024
Comorbidities
 Overall comorbidities, n (%)   80 (28.7%)  64 (19.8%)  16 (45.7%)  < 0.001
 Arterial hypertension, n (%)   58 (16.2%)  48 (14.8%)  10 (28.6%)  0.036
 COPD, n (%)   17 (4.7%)  10 (3.1%)  7 (20.0%)  < 0.001
 Dyslipoproteinemia, n (%)   35 (9.7%)  31 (9.6%)  4 (11.4%)  0.72
 Diabetes, n (%)   10 (2.8%)  8 (2.5%)  2 (5.7%)  0.27
Initial clinical condition
 Lower RTI, n (%)   196 (54.6%)  165 (50.9%)  31 (88.6%)  < 0.001
 Upper RTI, n (%)   163 (45.4%)  159 (49.1%)  4 (11.4%)  < 0.001
Laboratory findings, baseline (n = 350)
 MR-proANP, median, pmol/L (IQR)  47.7 (35.0, 75.5)  45.6 (34.2, 68.3)  80.5 (58.6, 126.0)  < 0.001
Laboratory findings, at day 7 (n = 334)
 MR-proANP, median, pmol/L (IQR)  54.7 (37.5, 79.3)  52.1 (37.0, 73.7)  91.4 (63.1, 150.0)  < 0.001
2° Outcomes (10-year follow-up)
 Adverse outcome, n (%)   52 (14.5%)  17 (5.2%)  35 (100.0%)  < 0.001
 MACCE, n (%)   19 (5.4%)  14 (4.3%)  5 (16.7%)  0.004
 Myocardial infarction, n (%)   9 (2.5%)  5 (1.5%)  4 (13.3%)  < 0.001
 Stroke, n (%)   8 (2.3%)  6 (1.9%)  2 (6.7%)  0.090
Data are presented as median (IQR) or % (no.). Comorbidities were identified based on medical record of general practitioner, patient report, 
or both. p-Values are statistically significant at p < 0.05. Blood levels are presented in pmol/L. IQR, interquartile range (25th–75th percentiles); 
SD, standard deviation; CV, cardiovascular; COPD, chronic obstructive lung disease; ARTI, acute respiratory tract infection.
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regression analysis where MR-proANP blood levels at base-
line showed a significant association with all-cause mortal-
ity (unadjusted HR: 3.5 [95% CI (confidence interval) 2.4–5.1, 
p < 0.001]; age-adjusted HR: 2.0 [95% CI 1.3–3.1, p = 0.002]). 
The results also remained robust in a fully adjusted model 
including age, gender, randomisation arm, antibiotic use 
initially, smoking history, comorbidities and type of infec-
tion (fully adjusted model HR: 2 [95% CI 1.2–3.3, p = 0.005]). 
Also, baseline and day 7 MR-proANP levels showed high dis-
crimination with AUCs of 0.79 and 0.74, respectively.
The prognostic accuracy of MR-proANP and all-cause 
mortality prediction in different predefined subgroups is 
demonstrated in Figure 2. There was no evidence for effect 
modification between subgroups although in nonsmokers 
and the younger population ( ≤  60  years) the prognostic 
accuracy of the marker tended to be stronger.
Further, we compared a clinical and demographic 
model, including the variables age, gender, randomisation 
arm, antibiotic use initially, smoking history, comorbidities 
and type of infection, with a model additionally including 
MR-proANP. Thereby, we found that MR-proANP improves 
the model from an AUC of 0.94 to 0.95 with a p-value of 0.067.
We also calculated accuracy measures including 
sensitivity, specificity and predictive values at different 
MR-proANP cut-off levels (see Supplemental Table 2). 
As demonstrated, the optimal cut-off generated with the 
Youden index was at a MR-proANP value of 58.5 pmol/L at 
baseline and 66.2 pmol/L at day 7.
Secondary outcomes: 10-year incidence 
of adverse outcome events
Ten-year incidence of an adverse outcome, defined as 
death, pulmonary embolism or MACCEs, was 52 (14.5%). 
Again, MR-proANP blood levels were elevated in the 
patients reaching this outcome at baseline and at day 7 
compared to patients not having an event. Cox regression 
models found associations with fair discrimination. The 
HRs for adverse outcome showed an association for MR-
proANP measurement on the day of randomization (unad-
justed HR: 3.0 [95% CI 2.1–4.3, p < 0.001]; age-adjusted HR: 
1.6 [95% CI 1.1–2.5, p = 0.025]; fully adjusted model HR: 1.5 
[95% CI 1.0–2.4, p = 0.070]) (see Table 3). The analysis of 
most subgroups presents significant associations for the 
unadjusted but not for the adjusted model (see Supple-
mental Tables 3 and 4).
Additionally, we explored associations of MR-proANP 
and the different components of the adverse outcome 
endpoint. The unadjusted HRs showed a significant 
association for MR-proANP measurement on the day of 
randomization, but not when adjusting for age; MACCE 
(unadjusted HR: 2.2 [95% CI 1.1–4.1, p = 0.021], age-
adjusted HR: 1.1 [95% CI 0.5–2.4, p = 0.815]); myocardial 
infarction (unadjusted HR: 2.2 [95% CI 1.1–4.1, p = 0.021], 
age-adjusted HR: 1.1 [95% CI 0.5–2.4, p = 0.815]) and stroke 
(unadjusted HR: 2.4 [95% CI 0.9–5.9, p = 0.068], age-
adjusted HR: 1.5 [95% CI 0.5–4.4, p = 0.501]) (Table 3). The 
specific subgroup analysis is presented in the Supplemen-
tal Material (Tables 3 and 4).
Discussion
Within this post-hoc, observational analysis of 359 patients 
visiting their general practitioners for a respiratory infec-
tion, we investigated the ability of a CV biomarker for long-
term outcome prediction over a 10-year period. We found 
that MR-proANP measured during the index visit and 
Figure 1: Ten-year Kaplan-Meier survival and without adverse outcome curve according to baseline MR-proANP blood concentration.
Plots showing the association between endpoint and MR-proANP quartiles; 4th quartile vs. 1st–3rd quartile.
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Table 2: Association between MR-proANP blood levels at baseline and day 7 of follow-up and 10-year all-cause mortality.
 
 
 
 
    10-year all-cause mortality
Baseline blood samples   Day 7 blood samples
Overall mortality   n = 34   n = 31
 Unadjusted HR, p-value   3.5 (95% CI 2.4–5.1), p < 0.001   3.8 (95% CI 2.3–6), p < 0.001
 Adjusted for age HR   2 (95% CI 1.3–3.1), p = 0.002   2.1 (95% CI 1.2–3.7), p = 0.014
 Fully adjusted model HR   2 (95% CI 1.2–3.3), p = 0.005   2 (95% CI 1.1–3.7), p = 0.030
 AUC   0.79 (95% CI 0.7–0.9)   0.74 (95% CI 0.6–0.8)
Subgroups
Gender   pa = 0.800   pa = 0.179 
  Male   n = 20   n = 18
   Unadjusted HR   3.3 (95% CI 2–5.5), p < 0.001   3.2 (95% CI 1.8–5.6), p < 0.001
   Adjusted for age HR   1.9 (95% CI 1–3.4), p = 0.038   2.2 (95% CI 1–4.6), p = 0.041
   AUC   0.81 (95% CI 0.7–0.9)   0.79 (95% CI 0.7–0.9)
  Female   n = 14   n = 13
   Unadjusted HR   3.5 (95% CI 2–6.2), p < 0.001   4 (95% CI 1.7–9.2), p = 0.001
   Adjusted for age HR   1.9 (95% CI 1–3.8), p = 0.052   1.6 (95% CI 0.6–4), p = 0.322
   AUC   0.77 (95% CI 0.7–0.9)   0.67 (95% CI 0.5–0.9)
Nicotine abuse   pa = 0.608   pa = 0.896
 Smoker   n = 15   n = 14
   Unadjusted HR   2.6 (95% CI 1.5–4.5), p = 0.001   2.5 (95% CI 1.2–5.2), p = 0.016
   Adjusted for age HR   1.4 (95% CI 0.7–2.7), p = 0.355   1.2 (95% CI 0.5–2.9), p = 0.612
   AUC   0.72 (95% CI 0.6–0.9)   0.67 (95% CI 0.5–0.8)
 Nonsmoker   n = 19   n = 17
   Unadjusted HR   4.5 (95% CI 2.6–7.5), p<0.001   4.9 (95% CI 2.7–9), p < 0.001
   Adjusted for age HR   2.8 (95% CI 1.5–5.1), p = 0.001   3.3 (95% CI 1.5–7.4), p = 0.003
   AUC   0.85 (95% CI 0.8–0.9)   0.82 (95% CI 0.7–0.9)
Age   pa = 0.754   pa = 0.488 
  > 60 years   n = 31   n = 28
   Unadjusted HR   2 (95% CI 1.3–3.2), p = 0.002   2.2 (95% CI 1.2–4), p = 0.012
   Adjusted for gender   1.9 (95% CI 1.2–3), p = 0.006   2 (95% CI 1.1–3.8), p = 0.031
   AUC   0.65 (95% CI 0.5–0.8)   0.62 (95% CI 0.5–0.8)
   ≤  60 years   n = 3   n = 3
   Unadjusted HR   4.9 (95% CI 1.2–20.2), p = 0.028  4 (95% CI 0.9–16.8), p = 0.063
   Adjusted for gender   4.3 (95% CI 1.1–17.8), p = 0.041  3.3 (95% CI 0.8–13.6), p = 0.096
   AUC   0.89 (95% CI 0.8–1)   0.87 (95% CI 0.8–1)
ap-Value for subgroup interaction. Data for univariable, bivariable and multivariable analyses are given as HR (95% CI) and p-value. Data 
regarding prognostic analysis are given as AUC (95 %CI). A higher AUC reflects greater accuracy: 0.5, the null value, indicates coin-toss 
accuracy, while 1.0, the maximum value, indicates 100% accuracy. p-Values in bold type are statistically significant at p < 0.05. Univariable 
model includes: natural logarithmic value of MR-proANP blood concentrations. Bivariable model includes: natural logarithmic value of MR-
proANP blood concentrations and patient age or gender, depending on subgroup. Fully adjusted model includes: natural logarithmic value 
of MR-proANP blood concentrations and patient age, gender, randomisation arm, antibiotic use initially, smoking history, comorbidities and 
type of infection.
7  days later was a strong predictor for 10-year all-cause 
mortality with robust results across several subgroups. 
Also, MR-proANP was associated with a 10-year incidence 
of adverse clinical outcomes.
Previously, several observational studies found MR-
proANP to predict mortality and disease-specific compli-
cations. The majority of these studies, however, focused 
on inhospital cohorts particularly with patients after a CV 
event or with infections of the respiratory tract such as 
[1, 5–11, 24–27, 33, 45]. Two studies done by our research 
group found MR-ProANP to be a significant predictor for 
mortality and intensive care unit admission in patients 
with lower respiratory infection [27] and community-
acquired pneumonia [33]. We also found MR-ProANP 
to have comparable prognostic accuracy compared to 
other natriuretic peptides in pneumonia patients [45]. 
Data of community-dwelling patients with lower severity, 
however, are largely lacking. Herein, this 10-year follow-
up study closed this gap and found a strong prognostic 
value of this marker for mortality prediction and predic-
tion of adverse outcome in a heterogeneous outpatient-
based cohort with a respiratory tract infection.
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Figure 2: Forest plot of MR-proANPs prognostic accuracy in predict-
ing 10-year all-cause mortality at baseline and day 7 in different 
patients subgroups.
Table 3: Association between MR-proANP blood levels at baseline and day 7 of follow-up and 10-year poor 2° outcome.
  Adverse outcome   MACCE   Myocardial infarction   Stroke
Overall   n = 50   n = 17   n = 9   n = 7
 Unadjusted HR   3 (95% CI 2.1–4.3), 
p < 0.001
  2.2 (95% CI 1.1–4.1), 
p = 0.021
  2.6 (95% CI 1.2–6), 
p = 0.021
  2.4 (95% CI 0.9–5.9), 
p = 0.068
 Adjusted for age HR   1.6 (95% CI 1.1–2.5), 
p = 0.025
  1.1 (95% CI 0.5–2.4), 
p = 0.815
  1.3 (95% CI 0.5–3.6), 
p = 0.602
  1.5 (95% CI 0.5–4.4), 
p = 0.501
 Fully adjusted model HR   1.5 (95% CI 1.0–2.4), 
p = 0.070
  0.8 (95% CI 0.3–2.1), 
p = 0.694
  1.3 (95% CI 0.3–5.0), 
p = 0.723
  1.1 (95% CI 0.3–3.6), 
p = 0.917
 AUC   0.72 (95% CI 0.6–0.8)  0.63 (95% CI 0.5–0.8)  0.66 (95% CI 0.5–0.8)   0.60 (95% CI 0.4–0.8)
Overall at 7 days   n = 46   n = 17   n = 8   n = 7
 Unadjusted HR   2.8 (95% CI 1.9–4.3), 
p < 0.001
  2.1 (95% CI 1–4.3), 
p = 0.050
  2.7 (95% CI 1–7), 
p = 0.048
  2.7 (95% CI 1–7.5), 
p = 0.053
 Adjusted for age HR   1.5 (95% CI 0.9–2.5), 
p = 0.141
  1 (95% CI 0.5–2.4), 
p = 0.916
  1.3 (95% CI 0.4–4), 
p = 0.676
  1.7 (95% CI 0.5–5.4), 
p = 0.386
 Fully adjusted model HR   1.3 (95% CI 0.8–2.2), 
p = 0.297
  0.8 (95% CI 0.3–2.2), 
p = 0.708
  1.3 (95% CI 0.3 to 5.4), 
p = 0.680
  1.1 (95% CI 0.3–4.3), 
p = 0.883
 AUC   0.69 (95% CI 0.6–0.8)  0.63 (95% CI 0.5–0.8)  0.66 (95% CI 0.5–0.9)   0.65 (95% CI 0.4–0.9)
Data for univariable, bivariable and multivariable analyses are given as HR (95% CI) and p value. Data regarding prognostic analysis are 
given as AUC (95% CI). A higher AUC reflects greater accuracy: 0.5, the null value, indicates coin-toss accuracy, while 1.0, the maximum 
value, indicates 100% accuracy. p-Values in bold type are statistically significant at p < 0.05. Univariable model includes: natural logarithmic 
value of MR-proANP blood concentrations. Bivariable model includes: natural logarithmic value of MR-proANP blood concentrations and 
patient age or gender, depending on subgroup. Fully adjusted model includes: natural logarithmic value of MR-proANP blood concentrations 
and patient age, gender, randomisation arm, antibiotic use initially, smoking history, comorbidities and type of infection.
Müller et al. [27] showed in an emergency department 
setting that MR-proANP levels were significantly higher in 
patients with ARTI when compared with healthy controls, 
but they showed as well a positive association on admis-
sion with significantly higher blood levels in nonsurvivors 
when compared with survivors.
However, we had access to MR-proANP levels meas-
ured on admission to the general practitioners office, 
while patients were suffering from ARTI and 7 days later 
when the infection may have been cured. Interestingly, 
the prognostic accuracy of MR-proANP was similar for 
admission and day 7 levels suggesting that this marker 
may be used during an acute infection episode and in 
stable disease for long-term prognostication.
Thus, MR-proANP seems to be an early and sensitive 
marker for cardiac stress and may mirror both, the acute 
inflammatory response reflecting the severity of the acute 
disease and the pre-existing CV comorbidities.
As ANP influences fluid homeostasis, blood pressure 
and endothelial permeability [15, 16], it might directly 
raise the risk of adverse outcomes with higher blood 
concentrations. Evidence points to an inverse associa-
tion with intima media thickness or metabolic syndrome 
because of inhibitory effects of obesity and lipid/glucose 
alterations [35], but hypertension and increased arterial 
stiffness are positively associated with MR-proANP levels 
[46]. In our study we did not perform a more in-depth 
assessment of comorbidities including cardiac echogram 
which could have given insights into the pathophysiology 
and explained the observed associations.
Whether MR-proANP will improve clinical decision 
making in the future has not been defined but is likely 
to require additional data showing specific treatment 
implications [8]. Studies point toward the potential to be 
useful for targeting therapies with an angiotensin-con-
verting enzyme inhibitor in patients with stable ischemic 
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heart disease aimed at preventing adverse remodeling 
in patients with acute coronary syndrome. Notably, 
Sabatine et  al. [47] presented data among patients 
having a MR-proANP, level in the top quartile, where an 
angiotensin-converting enzyme inhibitor significantly 
reduced the risk of CV death or heart failure, whereas no 
benefit was observed among those with lower levels. If 
this interaction with MR-proANP and treatment is sup-
ported by further evidence, it is possible that clinical 
application could be applied not only to enhance risk 
stratification but also to select new or established ther-
apies i.e. to reduce the risk of heart failure after acute 
coronary  syndrome [8].
Similarly, a previous large study (BACH) focused 
on patients with acute dyspnea. Based on their results, 
Daniels et  al. [48] recommended a cut-off point of 120 
pmol/L to rule out heart failure. Although sex and BMI 
were associated with MR-proANP levels, these factors did 
not have an influence on the diagnostic performance of 
MR-proANP. Also, Heining et al. [49] investigated the diag-
nostic measures of MR-proANP for the diagnosis of heart 
failure at the 120 pmol/L cut-off and found high sensitivity 
of 91.1% and an NPV (negative predictive value) of 92.1%. 
In the absence of atrial fibrillation, Richards et  al. [50] 
found an optimal cut-off of 210 pg/mL for MR-proANP to 
rule out heart failure, which was higher in patients with 
atrial fibrillation (370 pg/mL).
Concerning all-cause mortality at 3 months in patients 
with coronary artery disease, Haehling et  al. [51] found 
an optimal cut-off value of 236 pmol/L, and in patients 
with heart failure, the optimal prognostic accuracy was at 
295 pmol/L for 24 month survival [28].
In comparison, our study with a younger population 
shows a lower optimal cut-off level of 58.5 pmol/L for 
long-term 10-year survival (Table 2).
The result of our 10-year follow-up study is in-line with 
the existing literature. Especially, for the prediction of all-
cause mortality, MR-proANP seems to be a valid tool in the 
general practitioner setting as well as in the emergency 
department. Further, MR-proANP has the strongest pre-
dictive value in combination with correlated biomarkers, 
particularly brain natriuretic peptide (BNP), N-terminal 
pro-BNP (NT-proBNP), or midregional pro-adrenomedul-
lin (MR-proADM) and in subanalysis even outperformed 
them in their accuracy [10, 28, 52]. Our results confirm 
the existing knowledge that MR-proANP can be regarded 
as third valid natriuretic peptide besides NT-proBNP and 
BNP. However, there are studies like Eggers et  al. [36] 
where MR-proANP tended to show less distinct associa-
tions to left ventricular abnormalities and mortality, par-
ticularly compared to NT-proBNP.
We compared AUCs for 10-year all-cause mortality of 
a clinical and demographic model with a model addition-
ally including MR-proANP and calculated that MR-proANP 
improves the model from an AUC of 0.94 to 0.95 with a 
p-value of 0.067. However, we believe these models are 
much too optimistic with a limited sensitivity of the method 
due to over-fitting issues and are to be treated with caution. 
We therefore focused on the comparison of MR-proANP with 
our endpoints without the clinical and demographic model.
Nonetheless, according to our analysis MR-proANP is 
superior to copeptin, another osmo-dependent stress and 
inflammatory biomarker, in mortality prediction in the 
primary care setting [43] (see Supplemental Table 5).
CV risk assessment is important for clinical practice 
and common risk scores, e.g. Framingham score or AGLA 
score, remain the standard of care for prognostication. 
Nevertheless, biomarkers such as MR-proANP provide 
further reference for mortality prediction in community 
patients and add an additional benefit to concomitant 
laboratory values and established risk scores. This in 
turn might result in more personalized treatment consid-
erations thereby reducing hospitalizations or outpatient 
visits, and thus has the potential of reducing health care 
costs. In regard to the recently enhanced assay design of 
MR-proANP, the prognostic accuracy might have been 
underestimated in the last years and clinical use of this 
biomarker might increase [7].
The strengths of this study include the long follow-up 
period of 10 years, the participation of multiple primary 
care practices, and the sample of community-dwelling 
patients with respiratory tract infections representative 
for an outpatient population.
The following limitations require consideration: first, 
while the register of deaths could confirm survival status 
of patients, no information was available on the cause of 
death. Also, there is the possibility that general practition-
ers have not seen their patients on a regular basis, or rela-
tives did not remember medical information. Therefore, 
assessment of the data was not consistent and we limited 
our analysis to all-cause rather than to cause-specific mor-
tality. Second, the incomplete baseline risk assessment in 
the original cohort, e.g. blood parameters such as lipid 
values or blood pressure, do not allow us to investigate 
whether MR-proANP would improve state-of-the-art risk 
scores (e.g. Framingham risk score). It will thus be impor-
tant to investigate MR-proANP in cohorts of patients with 
more rigorous assessment of CV risk factors in the future. 
Third, our sample was small in size. Thus we were not 
able to analyze further short-term adverse outcomes and 
the power to show significant associations with some of 
the outcomes is low. Lastly, our follow-up rate was 78.5%.
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Conclusions
In a sample of patients visiting their general practitioner 
for a respiratory infection, MR-proANP was associated 
with 10-year all-cause mortality and adverse outcome 
including death, pulmonary embolism, and MACCE. 
These results suggest that MR-proANP could be used in 
future research looking at long-term prognostication in 
primary care patients and may also prove useful as a com-
panion diagnostic for primary prevention measures.
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